A single ketamine infusion typically reduces OCD symptoms for one to seven days, with some patients reporting relief lasting up to two weeks. The effects begin remarkably fast, often within the 40-minute infusion itself, but they are temporary. That short window of relief is both ketamine’s biggest advantage and its most significant limitation for people with OCD.
How Quickly Ketamine Works for OCD
In clinical studies, patients have reported noticeable drops in obsessive-compulsive symptoms midway through a standard 40-minute intravenous infusion. By two hours after the infusion ends, symptom scores on standardized scales can shift from “severe” to “moderate.” That speed is striking compared to conventional OCD medications, which often take 8 to 12 weeks to reach full effect.
Research led by Carolyn Rodriguez at Stanford found that patients experienced dramatic decreases in obsessions and compulsions during the infusion itself. One patient’s OCD symptoms disappeared immediately and remained gone for two weeks afterward. That kind of rapid response is what makes ketamine attractive for people who haven’t responded to standard treatments, though not everyone experiences results that dramatic.
How Long the Relief Lasts
The anti-obsessive effects of a single infusion generally persist for one to seven days. In the Stanford study, about half of patients maintained reduced symptoms throughout the following week. A smaller number saw benefits stretch to around two weeks. After that, symptoms typically return toward their baseline without additional treatment.
This timeline varies from person to person. Factors like symptom severity, how long someone has had OCD, and whether they’re on other medications all seem to influence duration. But across studies, the pattern is consistent: ketamine provides a rapid but temporary reduction in OCD symptoms, not a lasting cure from a single dose.
Why the Effects Fade
Ketamine works through a different brain pathway than the standard medications used for OCD. Rather than targeting serotonin, it acts on a signaling system involving glutamate, the brain’s primary excitatory chemical messenger. At the low doses used in psychiatric treatment, ketamine triggers a temporary surge in glutamate activity in the prefrontal cortex, the brain region involved in decision-making and impulse control.
That surge appears to strengthen connections between brain cells in the short term. The brain essentially gets a boost in prefrontal connectivity, which may help override the stuck, looping thought patterns characteristic of OCD. But the effect is driven by a temporary chemical shift, not a permanent structural change. Once the downstream signaling fades, the brain’s default wiring reasserts itself, and obsessive-compulsive patterns tend to reemerge.
What Repeated Infusions Look Like
Because a single infusion wears off within days, some clinics offer repeated sessions to extend the benefit. There is no widely agreed-upon maintenance schedule for OCD specifically. Protocols vary between providers, and the evidence base for long-term repeated ketamine use in OCD is still thin compared to its use in depression. Most published data comes from small studies and case reports rather than large trials.
In practice, an initial course might involve several infusions over one to two weeks, followed by periodic boosters. The goal is to sustain the symptom reduction while the patient engages in therapy, particularly exposure and response prevention, which remains the gold-standard psychological treatment for OCD. Some clinicians view ketamine’s rapid relief as a window of opportunity: a period when obsessive thoughts are quieter and a patient may be more able to do the difficult work of behavioral therapy.
Who Qualifies for Ketamine Treatment
Ketamine for OCD is not a first-line option. It’s generally reserved for people with treatment-resistant OCD, which researchers have defined as failing to respond to at least two adequate trials of conventional medications and at least one course of appropriate psychotherapy. In clinical trials, participants typically had severe symptoms, scoring above 26 on the Yale-Brown Obsessive Compulsive Scale (a 40-point measure where higher scores indicate worse symptoms).
A meaningful treatment response in these studies was defined as a 35% or greater reduction in symptom scores. Not everyone hits that threshold. The research so far suggests ketamine helps a subset of people with severe, resistant OCD, but it’s not universally effective, and predicting who will respond remains difficult.
Current Approval Status
Ketamine is not FDA-approved for OCD or any other psychiatric disorder. Its only approved use is as an anesthetic. A related nasal spray called esketamine (Spravato) is approved for treatment-resistant depression, but that approval does not extend to OCD. Any use of ketamine for OCD is considered off-label, meaning a doctor prescribes it based on clinical judgment and emerging evidence rather than formal regulatory approval.
The FDA has specifically warned about compounded ketamine products marketed for psychiatric conditions, noting that these have not been evaluated for safety or effectiveness in treating disorders like OCD. This doesn’t mean ketamine can’t help, but it does mean the evidence hasn’t yet met the bar required for formal approval. Clinical trials are ongoing, and the landscape could change, but for now, anyone pursuing this option should understand that it sits outside the standard treatment framework.
What to Realistically Expect
If you’re considering ketamine for OCD, the most honest summary is this: it can work fast and the relief can be meaningful, but it doesn’t last long on its own. A single infusion is likely to reduce symptoms within hours, with that improvement fading over the course of one to two weeks. Repeated infusions may extend the benefit, but there’s no established long-term protocol, and the costs of ongoing treatment add up quickly since most insurance plans don’t cover off-label ketamine infusions.
The experience of the infusion itself involves a subanesthetic dose delivered intravenously over about 40 minutes. Side effects during and shortly after the session can include dissociation (feeling detached from your body or surroundings), dizziness, nausea, and temporary increases in blood pressure. These effects generally resolve within a couple of hours. The anti-OCD benefits, when they occur, outlast these acute side effects by days.
For people with severe, treatment-resistant OCD who have exhausted conventional options, ketamine represents a genuinely different mechanism of action and a speed of relief that nothing else currently matches. The challenge is turning that short-term relief into lasting improvement, which likely requires combining the infusions with ongoing therapy and other treatments.